|By Marketwired .||
|July 16, 2014 08:20 AM EDT||
SYDNEY, AUSTRALIA -- (Marketwired) -- 07/16/14 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces that the US patent number 8,771,701 titled "Compositions for immunotherapy and uses thereof", which protects the Company's CVac technology, has been granted by the United States Patent and Trademark Office (USPTO).
Prima has also received a patent term adjustment of 1,409 days for US 8,771,701, extending the patent expiry date for the US market to August 2022.
Chief Executive Officer of Prima, Mr. Marc Voigt, said: "The grant of this key US patent with a patent term adjustment of almost four years is an important value proposition for Prima. The patent term can potentially be further extended by up to five years if CVac receives market approval before it expires, which would provide the Company with essential protection over its commercial development well into the future."
The patent grant protects the method of composition and the method of use of CVac, which is formulated in a patient's own dendritic cells and then reinjected back into the patient to generate a cytotoxic T cell response against the mucin 1 antigen. CVac is a personalised immunotherapy composed of a patient's own dendritic cells pulsed with the cancer antigen mucin 1, conjugated to oxidised mannan.
The patent grant follows receipt of the Notice of Allowance from the USPTO in relation to Patent Application 11/561,204 as announced on 26 May 2014. It completes the granting of all patents relevant to the CVac technology. Other territories that have received patent approval include Australia, Canada, Europe and Japan.
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
For further information please contact:
+1 (646) 862 4607
Mr Matthew Gregorowski
+61 (0) 422 534 755
Mr. Axel Muhlhaus
+49 (0) 69 905505-52
In 2014, the market witnessed a massive migration to the cloud as enterprises finally overcame their fears of the cloud’s viability, security, etc. Over the past 18 months, AWS, Google and Microsoft have waged an ongoing battle through a wave of price cuts and new features. For IT executives, sorting through all the noise to make the best cloud investment decisions has become daunting. Enterprises can and are moving away from a "one size fits all" cloud approach. The new competitive field has ...
Sep. 4, 2015 11:00 AM EDT Reads: 186
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
Sep. 4, 2015 11:00 AM EDT Reads: 421
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...
Sep. 4, 2015 11:00 AM EDT Reads: 243
17th Cloud Expo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises ar...
Sep. 4, 2015 11:00 AM EDT Reads: 1,609
Sep. 4, 2015 10:45 AM EDT Reads: 660
Sep. 4, 2015 10:15 AM EDT Reads: 128
Sep. 4, 2015 10:00 AM EDT Reads: 870
Sep. 4, 2015 10:00 AM EDT Reads: 135
Sep. 4, 2015 10:00 AM EDT Reads: 145
Sep. 4, 2015 09:45 AM EDT Reads: 160
Sep. 4, 2015 09:30 AM EDT Reads: 334
Sep. 4, 2015 09:15 AM EDT Reads: 382
Sep. 4, 2015 09:15 AM EDT Reads: 156
Enterprises can achieve rigorous IT security as well as improved DevOps practices and Cloud economics by taking a new, cloud-native approach to application delivery. Because the attack surface for cloud applications is dramatically different than for highly controlled data centers, a disciplined and multi-layered approach that spans all of your processes, staff, vendors and technologies is required. This may sound expensive and time consuming to achieve as you plan how to move selected applicati...
Sep. 4, 2015 09:15 AM EDT Reads: 150
Containers are not new, but renewed commitments to performance, flexibility, and agility have propelled them to the top of the agenda today. By working without the need for virtualization and its overhead, containers are seen as the perfect way to deploy apps and services across multiple clouds. Containers can handle anything from file types to operating systems and services, including microservices. What are microservices? Unlike what the name implies, microservices are not necessarily small,...
Sep. 4, 2015 09:00 AM EDT Reads: 206